Hot Pursuit     06-Aug-21
Narayana Hrudayalaya Q1 FY22 PAT turnaround to Rs 76 cr
Narayana Hrudayalaya jumped 6.22% to Rs 534.80 after the company's consolidated net profit stood at Rs 76.24 crore in Q1 June 2021 (Q1 FY22) as compared to a net loss of Rs 119.76 crore in Q1 June 2020 (Q1 FY21).

Consolidated net sales soared 118.5% to Rs 859.80 crore in Q1 FY22 from Rs 393.50 crore in Q1 FY21. Pre-tax profit was at Rs 77.11 crore in Q1 FY22 as against a pre-tax loss of Rs 153.45 crore in Q1 FY21. The Q1 earnings were declared post trading hours yesterday, 5 August 2021.

Consolidated EBITDA stood at Rs 140.40 crore during the quarter, reflecting a margin of 16.3% as against loss of Rs 86.30 crore in Q1 FY21. As on 30 June 2021, the total borrowings less cash and bank balance was Rs 428 crore representing a net debt to equity ratio of 0.36. (out of which, debt worth $37.3 million is foreign currency denominated).

Commenting on the Q1 performance, Dr Emmanuel Rupert, the managing director (MD) and group chief executive officer (CEO) of Narayana Hrudayalaya, stated: "With the impact of the devastating second wave of the pandemic playing out for much of the period in the quarter gone by, our Indian operations were affected on expected lines. Our flagship heart hospital at Health City, Bengaluru bore the brunt of the effect given its pre-eminence in the cardiac sciences based elective domain as well as higher reliance on out-of-station domestic and international patients. However, we are encouraged by the traction being demonstrated by our other units building upon the momentum over the previous few quarters. While the India business profitability was materially impacted as our hospitals were overwhelmed with COVID-19 patients with significant erosion in our high-end elective work, we are pleased that our overseas Cayman Island facility continued to deliver solid consistent performance in the quarter gone by."

"Looking ahead, we remain vigilant over recent developments taking place across some nations with respect to a fresh wave. Notwithstanding the near term COVID-19 related uncertainties, with vaccination rollout program picking up pace, we remain confident about our business prospects by continuing to focus on delivering quality affordable healthcare to all. Lastly, we do share the grief of all the affected and pledge to support our communities in these times."

Narayana Hrudayalaya operates a chain of multi specialty, tertiary and primary healthcare facilities.

Previous News
  Narayana Hrudayalaya consolidated net profit rises 10.15% in the March 2024 quarter
 ( Results - Announcements 25-May-24   07:40 )
  Narayana Hrudayalaya update on expansion in Cayman Island
 ( Corporate News - 19-Feb-21   17:56 )
  Vodafone Idea Ltd leads gainers in 'A' group
 ( Hot Pursuit - 06-Aug-21   12:00 )
  Volumes spurt at Zee Entertainment Enterprises Ltd counter
 ( Hot Pursuit - 14-Sep-21   14:30 )
  Board of Narayana Hrudayalaya recommends final dividend
 ( Corporate News - 25-May-24   10:28 )
  Narayana Hrudayalaya consolidated net profit rises 30.05% in the December 2020 quarter
 ( Results - Announcements 06-Feb-21   08:10 )
  Narayana Hrudayalaya to declare Quarterly Result
 ( Corporate News - 04-Aug-22   10:58 )
  Narayana Hrudayalaya announces board meeting date
 ( Corporate News - 08-Nov-23   15:39 )
  Narayana Hrudayalaya incorporates wholly owned subsidiary - NH Integrated Care
 ( Corporate News - 10-Jan-23   18:53 )
  Narayana Hrudayalaya to discuss results
 ( Corporate News - 26-Oct-18   10:41 )
  Volumes soar at Sadbhav Infrastructure Projects Ltd counter
 ( Hot Pursuit - 10-May-18   14:31 )
Other Stories
  Avantel Q2 PAT jumps 42% YoY to Rs 23 cr
  05-Oct-24   17:03
  Equitas SFB total deposits jump 29% YoY in Q2 FY25
  05-Oct-24   16:28
  Ujjivan SFB total deposits rises 17% in Q2 FY25
  05-Oct-24   15:34
  L&T Finance retail disbursements jump 12% YoY in Q2 FY25
  05-Oct-24   14:31
  Bandhan Bank records over 21% YoY jump in loan book during Q2 FY25; deposits at Rs 1.42 lakh crore
  05-Oct-24   13:32
  Lupin's Pune-based biotech facility gets 5 observations from US FDA
  05-Oct-24   13:20
  Macrotech Developers pre-sales jumps 21% YoY in Q2 FY25
  05-Oct-24   09:04
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
Back Top